窄带成像放大内镜联合胃蛋白酶原、胃泌素在胃癌诊断中的应用

摘要
图/表
参考文献(26)
相关文章 (9)

全文: PDF (598 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨窄带成像放大内镜联合血清胃蛋白酶原（PG）、胃泌素-17（G-17）对胃癌的诊断效果。方法选取2015年8月～2017年8月就诊于河北省沧州市中心医院消化内科的胃病患者172例，首先行PG和G-17检查，对结果异常者再行窄带成像放大内镜技术（NBI-ME）精查加病理，根据病理结果将入选患者分为非萎缩性胃炎组（对照组，50例）、萎缩性胃炎组（55例）、胃癌组（67例）。比较各组血清PGⅠ、PGR和G-17的水平及敏感度、特异度、阳性预测值、阴性预测值、准确度，评价其对胃癌的诊断效能。结果与对照组比较，萎缩性胃炎组、胃癌组的PGⅠ及PGR（PGⅠ/Ⅱ）水平降低，G-17水平升高（P ＜ 0.05）。与萎缩性胃炎组比较，胃癌组G-17水平升高，PGⅠ及PGR水平降低（P ＜ 0.05）。以病理结果为金标准，选择70 μg/L为临界值评价PGⅠ诊断胃癌的敏感度为71.87%，特异度为89.18%，准确度为56.39%；以7.0为临界值评价PGR诊断胃癌的敏感度为41.93%，特异度为82.97%，准确度为75.58%。以15 pmol/L为临界值评价G-17诊断胃癌的敏感度为60.61%，特异度为71.22%，准确度为69.19%。G-17联合PGR诊断胃癌的敏感度为51.35%，特异度为92.59%，准确度为83.72%。G-17联合PG诊断胃癌的敏感度为47.37%，特异度为83.58%，准确度为75.58%。结论经过PG和G-17联合筛查后行NBI-ME精查有助于提高胃癌的诊断率，值得临床推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	苏振华王亮魏思忱魏新亮孔郁王卫卫史晓盟郭瑞雪

关键词 ：胃癌, 胃蛋白酶原, 胃泌素-17, 窄带成像放大内镜

Abstract：Objective To discuss the effect of narrow-band imaging magnifying endoscopy (NBI-ME) combined with serum pepsinogen (PG) and gastrin (G-17) in diagnosis of gastric cancer. Methods A total of 172 patients treated in Department of Gastroenterology, Cangzhou Central Hospital from August 2015 to August 2017 were selected. Firstly, PG and G-17 were tested in the patients. Then, the NBI-ME plus pathology examination were further used to examine the patients with abnormal PG and G-17 results. According to the pathology results, all the patients were divided into non-atrophic gastritis group (control group, 50 cases), atrophic gastritis group (55 cases), and gastric carcer group (67 cases). The sensitivity, specific degree, positive predictive value, negative predictive value and accuracy of serum PGⅠ, PGR and G-17 among the three groups, and their effectiveness to the diagnosis of gastric cancer were evaluated. Results Compared with the control group, the levels of PGⅠ and PGR (PGⅠ/Ⅱ) were lower, and the level of G-17 was higher in the atrophic gastritis group and gastric cancer group (P ＜ 0.05). Compared with the atrophic gastritis group, the levels of G-17 was higher and PGⅠ, PGR were lower in the gastric cancer group (P ＜ 0.05). The pathology assay was used as the gold standard, the sensitivity of the PGⅠ with 70 μg/L as the diagnostic value in the diagnosis of gastric cancer was 71.87%, the specificity was 89.18%, and the accuracy was 56.39%. The sensitivity of the PGR with 7.0 as the diagnostic value diagnosis of gastric cancer was 41.93%, the specificity was 82.97%, and the accuracy was 75.58%. The sensitivity of G-17 with 15 pmol/L as the diagnostic value in the diagnosis of gastric cancer was 60.61%, the specificity was 71.22% and the accuracy was 69.19%. The sensitivity of G-17 combined with PGR in the diagnosis of gastric cancer was 51.35%, the specificity of 92.59% and the accuracy of 83.72%. The sensitivity of G-17 combined with PGⅠ in the diagnosis of gastric cancer was 43.37%, the specificity of 83.58% and the accuracy of 75.58%. Conclusion The combination of PG and G-17, followed with further examination of NBI-ME in the diagnosis of gastric cancer could improve the diagnostic rate in the early period, and it is worthy of clinical application.

Key words： Gastric cancer Pepsinogen Gastrin-17 Narrow-band imaging magnifying endoscopy

基金资助:河北省沧州市科技计划项目（151302139）。

通讯作者: 魏思忱（1968.2-），女，硕士，主任医师，河北省沧州市中心医院消化内科科主任；研究方向：消化系统肿瘤的诊断与治疗。

作者简介: 苏振华（1984.12-），男，硕士；研究方向：消化道早期癌的诊断与治疗。

引用本文:

苏振华王亮魏思忱魏新亮孔郁王卫卫史晓盟郭瑞雪. 窄带成像放大内镜联合胃蛋白酶原、胃泌素在胃癌诊断中的应用[J]. 中国医药导报, 2018, 15(29): 124-128.
SU Zhenhua WANG Liang WEI Sichen WEI Xinliang KONG Yu WANG Weiwei SHI Xiaomeng GUO Ruixue. The appication of narrow-band imaging magnifying endoscopy combined with serum pepsinogen and gastrin in the diagnosis of gastric cancer. 中国医药导报, 2018, 15(29): 124-128.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2018/V15/I29/124

[1] Torre LA，Bray F，Siegel ＲL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[2] 朱敏，李明阳，吴本俨.早期胃癌内镜下切除术后复发的相关因素分析[J].中华内科杂志，2011，50（5）：366-369.
[3] 司望利，王田芳，庄坤，等.放大内镜结合窄带成像技术在早期胃癌诊断中的应用[J].临床医学研究与实践，2016， 1（24）：192-194.
[4] 刘松华，莫湘，文黛薇，等.NBI联合放大内镜对早期胃癌及癌前病变的观察研究[J].中国医药科学，2016，6（8）：23-26，131.
[5] 吴冠楠，姚学权，刘福坤.血清胃蛋白酶原对早期胃癌检测的研究进展[J].检验医学与临床，2015，12（14）：2126-2128.
[6] Yamaguchi Y，Nagata Y，Hiratsuka R，et al. Gastric Cancer Screening by Combined Assay for Serum Anti-Helicobacter pylori IgG Antibody and Serum Pepsinogen Levels-The ABC Method [J]. Digestion，2016，93（1）：13-18.
[7] 苏振华，魏思忱，王亮.窄带成像放大内镜诊断慢性萎缩性胃炎的价值[J].胃肠病学，2015，11（20）：676-679.
[8] 朱春平.“中国早期胃癌筛查方案”国际研讨会成功举办[J].中华消化内镜杂志，2015，32（2）：85.
[9] 潘锋.内镜是消化道恶性肿瘤筛查早诊早治核心技术——访中国医学科学院肿瘤医院内镜科主任王贵齐教授[J].中国当代医药，2018，25（14）：1-3.
[10] 中华医学会消化内镜学分会病理学协作组.中国消化内镜活组织检查与病理学检查规范专家共识（草案）[J].中华消化内镜杂志，2014，31（9）：481-485.
[11] 中华医学会消化病学分会.中国慢性胃炎共识意见（2017，上海）[J].胃肠病学，2017，22（11）：670-687.
[12] 中华医学会消化内镜学分会，中国抗癌协会肿瘤内镜专业委员会.中国早期胃癌筛查及内镜诊治共识意见（2014年，长沙）[J].中华消化杂志，2014，34（7）：433-448.
[13] Xu M，Liu M，Du X，et al. Intratumoral delivery of IL-21 overcomes anti-Her2/Neu resistance through shifting tumor-associated macrophages from M2 to M1 phenotype [J]. J Immunol，2015，194（10）：4997-5006.
[14] Hosseii M，Amoueia S，Attaranzadeh S，et al. Serum gastrin 17，pepsinogen I and II in atrophic gastritis patients living in North -East of Iran [J]. J Res Med Sci，2013，18（3）：225-229.
[15] Boltin D，Gingold-Belfer R，Dickman R，et al. Gastric mucin expression in first degree relarives of gastric cancer patients [J]. Eur J Gastroenterol Hepatol，2014，26（7）：710-714.
[16] Nakajima S. Roles of pepsinogen test，ABC method and barium X-ray examination on gastric cancer screening [J]. Nihon Shokakibyo Gakkai Zasshi，2013，110（2）：225-233.
[17] Liu ZJ，Guo ZJ，Zhao ZX，et al. Serological assessment of gastric mucosa using pepsinogens，gastrin-17 and Hp-IgG in patients with gastric cancer and atrophic gastritis [J]. Labeled Immunoassays Clinical Medicine，2014，101（1）：763-764.
[18] Yakut M，Ormeci N，Erdal H，et al. The association between precancerous gastric lesions and serumpepsinogens serum gastrin vascular endothelial growth factor serum interleukin-1 beta serum toll-like receptor-4 levels and Helicobacter pylori Cag A status [J]. Clin Res Hepatol Gastroenterpl，2013，37（3）：302-311.
[19] Massarrat S，Haj-Sheykholeslami A. Increased serum pep-sinogen Ⅱ level as a marker of pangastritis and corpus-predominant gastritis in gastric cancer prevention [J]. Archives of Iranian Medicine，2016，19（2）：137-140.
[20] Kitahara F，Kobayashi K，Sato T，et al. Accuracy of screening for gastric cancer using serum pepsinogen coneentrations [J]. Gut，1999，44（5）：693-697.
[21] Shiotani A，Iishi H，Uedo N，et al. Histologic and serum risk marker for noncardia ealy cancer [J]. Int J Cancer，2005,115（3）：463-469.
[22] Sun L，Tu H，Liu J，et al. A comprehensive evaluation of fasting secreum gastrin-17 as a predictor of diseased stomach in Chinese population [J]. Scand J Gastroenterol，2014，49（10）：1164-1172.
[23] 朱春平，赵建业，申晓军，等.血清胃泌素-17联合胃蛋白酶原检测对胃癌诊断界值的多中心临床研究[J].中华消化内镜杂志，2017，34（1）：19-23.
[24] Yamada S，Doyama H，Yao K，et al. An efficient diagnostic strategy for small, depressed early gastric cancer with magnifying narrow-band imaging：a post-hoc analysis of a prospective randomized controlled trial [J]. Gastrointest Endosc，2014，79（1）：55-63.
[25] Zhang Q，Wang F，Chen ZY，et al. Diagnostic ability of magnifying endoscopy with blue laser imaging for early gastric cancer：a prospective study [J]. Gastric Cancer，2017， 20（2）：297-303.
[26] 宋洁莹，李海燕，朱凌音，等.放大内镜结合窄带成像技术指导活检对诊断早期胃癌的重要性[J].中华消化内镜杂志，2014，31（8）：455-458.